Proteins with enhanced functionality and methods of making novel proteins using circular permutation
The present disclosure is relates to novel proteins and peptides having novel and/or enhanced functions and/or behaviors with respect to a native protein or peptide, and methods of making the novel proteins and peptides using techniques of circular permutation and protein engineering.
1. A circularly permuted protein comprising:
lipase B from Candida Antarctica (CALB);
a linker sequence linking a native amino-terminal end of CALB and a native carboxy-terminal end of CALB; and
a new amino-terminal end and a new carboxy-terminal end, wherein the new amino-terminal and carboxy-terminal ends of the circularly permuted protein are different from the native amino-terminal and carboxy-terminal ends of a corresponding native CALB protein, wherein the new amino-terminal end is located at an amino acid residue corresponding to an amino acid residue of the CALB protein SEQ ID No: 2 selected from: 144, 148, 150, 268, 277, 278, 283, 284, 289, and 294,
wherein the circularly permuted protein comprises at least one improvement over the corresponding native CALB protein, wherein the improvement is selected from: increased activity, increased accessibility to the active site, increased flexibility of the active site, increased the enantioselectivity, and broader or changed substrate specificity.
2. The circularly permuted protein of claim 1 , wherein the circularly permuted protein has an active site and wherein, when the circularly permuted protein is in a folded confirmation, the new amino terminal and carboxy terminal ends are located near the active site of the protein.
3. The circularly permuted protein of claim 1 , wherein the circularly permuted protein has increased accessibility to the active site over that of the native protein.
4. The circularly permuted protein of claim 3 , wherein the increased active site accessibility allows the circularly permuted protein to couple to at least one substrate that the corresponding native protein is substantially unable to couple.
5. The circularly permuted protein of claim 3 , wherein the increased active site accessibility broadens or changes the substrate specificity of the circularly permuted protein over that of the corresponding native protein.
6. The circularly permuted protein of claim 1 , wherein the circularly permuted protein has increased flexibility to the active site as compared to that of the corresponding native protein.
7. The circularly permuted protein of claim 1 , wherein the circularly permuted protein has substantially similar or increased enantioselectivity over that of the corresponding native protein.
8. The circularly permuted protein of claim 1 , wherein the circularly permuted protein has increased activity over that of the corresponding native protein.
9. The circularly permuted protein of claim 1 , wherein the protein is immobilized to a surface.
10. The circularly permuted protein of claim 9 , wherein the protein is immobilized to a matrix material.
11. The circularly permuted protein of claim 9 , wherein the immobilization increases the stability of the circularly permuted protein.
12. A circularly permuted protein comprising:
lipase B from Candida Antarctica (CALB) having an original amino acid sequence comprising the amino acid sequence of SEQ ID No: 2;
a linker sequence linking an original amino-terminal end of CALB and an original caboxy-terminal end of CALB; and
a new amino-terminal end and a new carboxy-terminal end, wherein the new amino-terminal and carboxy-terminal ends of the circularly permuted protein of the α/β-hydrolase fold family are different from the original amino-terminal and carboxy-terminal ends of a corresponding native CALB protein, wherein the new amino-terminal end is located in a region of the corresponding native CALB protein selected from: α7, α9, α16 and α17;
wherein the circularly permuted protein comprises at least one improvement over the corresponding native CALB protein, wherein the improvement is selected from: increased activity, increased accessibility to the active site, increased flexibility of the active site, increased the enantioselectivity, and broader or changed substrate specificity.
13. The circularly permuted protein of claim 12 , wherein the circularly permuted protein has an active site and wherein, when the circularly permuted protein is in a folded confirmation, the new amino terminal and carboxy terminal ends are located near the active site.
14. The circularly permuted protein of claim 12 , wherein the circularly permuted protein has a cap domain corresponding to a cap domain of the native CALB protein and wherein, when the circularly permuted protein is in a folded confirmation, the new amino terminal and carboxy terminal ends are located in the cap domain.
15. The circularly permuted protein of claim 12 , wherein the protein has increased accessibility to the active site over that of the native protein.
16. The circularly permuted protein of claim 15 , wherein the increased active site accessibility allows the circularly permuted protein to couple to at least one substrate that the corresponding native protein is substantially unable to couple.
17. The circularly permuted protein of claim 15 , wherein the increased active site accessibility allows the circularly permuted protein to couple esters and amides.
18. The circularly permuted protein of claim 17 , wherein the esters are selected from: esters of primary alcohols, esters of secondary alcohols, and esters of tertiary alcohols.
19. The circularly permuted protein of claim 12 , wherein the protein has increased flexibility to the active site as compared to that of the corresponding native protein.
20. The circularly permuted protein of claim 12 , wherein the protein has substantially similar or increased enantioselectivity over that of the corresponding native protein.
21. The circularly permuted protein of claim 12 , wherein the protein has increased activity over that of the corresponding native protein.
22. The circularly permuted protein of claim 12 , wherein the protein is immobilized to a surface.
23. The circularly permuted protein of claim 12 , wherein the new amino-terminal end is located at a residue corresponding to an amino acid residue of SEQ ID No: 2 selected from: 144, 148, 150, 193, 268, 277, 278, 283, 284, 289, and 294.
24. The circularly permuted protein of claim 12 , wherein the new amino-terminal end is located at a residue corresponding to residue 283 of SEQ ID No: 2.
25. The circularly permuted protein of claim 12 , wherein the circularly permuted protein is cp283 having SEQ ID No: 14, wherein cp283 comprises an external loop region comprising the original amino-terminal and carboxy-terminal ends of the corresponding native protein and the linker sequence, and wherein the secondary mutation comprises a deletion of one or more amino acids in the external loop region.
26. The circularly permuted protein of claim 25 , wherein the deletion of one or more amino acids in the external loop region results in a second circularly permuted protein, and wherein the second circularly permuted protein has substantially similar or increased activity over cp283 and has increased stability over cp283.
27. A circularly permuted protein comprising:
lipase B from Candida Antarctica (CALB), wherein an original amino-terminal end and an original carboxy-terminal end of CALB have been linked together;
a new amino-terminal end and a new carboxy-terminal end, wherein the new amino-terminal and carboxy-terminal ends of the circularly permuted protein are different from the original amino-terminal and carboxy-terminal ends of a corresponding native CALB protein, wherein the new amino-terminal end is located at an amino acid residue corresponding to an amino acid residue of SEQ ID No: 2 selected from: 144, 148, 150, 268, 277, 278, 283, 284, 289, and 294, wherein the circularly permuted protein comprises at least one improvement over the corresponding native CALB protein, wherein the improvement is selected from: increased activity, increased accessibility to the active site, increased flexibility of the active site, increased the enantioselectivity, and broader or changed substrate specificity.
28. The circularly permuted protein of claim 1 , wherein the circularly permuted protein is cp283 comprising SEQ ID No: 14.
29. The circularly permuted protein of claim 1 , wherein the new amino-terminal end is located at a residue corresponding to residue 283 of SEQ ID NO: 2.
30. The circularly permuted protein of claim 29 , wherein the circularly permuted protein is cp283 having SEQ ID No: 14, wherein cp283 comprises an external loop region comprising the original amino-terminal and carboxy-terminal ends of the corresponding native protein and the linker sequence, and wherein the circularly permuted protein further comprises a secondary mutation comprising a deletion of one or more amino acids in the external loop region.
31. The circularly permuted protein of claim 30 , wherein the deletion of one or more amino acids in the external loop region results in a second circularly permuted protein, and wherein the second circularly permuted protein has substantially similar or increased activity over cp283 and has increased stability over cp283.